• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Table 6.3Results of the cost-effectiveness analysis comparing treatment for MSCC versus no treatment: scenario 2

Scenario 2Average cost per patient (£)Average survival per patient (months)Average time ambulant per patient (months)Average QALYs per patientICER: [increment] Cost per QALY (£)
RT alone30,5237.131.900.153,309
No treatment30,2087.130.000.06
Vertebroplasty37,74910.996.490.42Dominant
No treatment48,67311.570.000.10
Major surgery40,51610.996.490.42Dominant
No treatment48,67311.570.000.10

From: 6, Treatment of spinal metastases and MSCC

Cover of Metastatic Spinal Cord Compression
Metastatic Spinal Cord Compression: Diagnosis and Management of Patients at Risk of or with Metastatic Spinal Cord Compression.
NICE Clinical Guidelines, No. 75.
National Collaborating Centre for Cancer (UK).
Copyright © 2008, National Collaborating Centre for Cancer.

No part of this publication may be reproduced, stored or transmitted in any form or by any means, without the prior written permission of the publisher or, in the case of reprographic reproduction, in accordance with the terms of licenses issued by the Copyright Licensing Agency in the UK. Enquiries concerning reproduction outside the terms stated here should be sent to the publisher at the UK address printed on this page.

The use of registered names, trademarks etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant laws and regulations and therefore for general use.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.